| Similar Articles |
|---|
 |
The Motley Fool
May 15, 2008
Brian Orelli |
So-So Syneron A little growth is an acceptable outcome in the struggling medical laser industry.   |
The Motley Fool
May 15, 2006
Stephen D. Simpson |
Sales and Marketing Slam Syneron Higher expenses and disappointing results leave the med-tech stock suffering. |
The Motley Fool
December 7, 2006
Matt Koppenheffer |
The Best Small Cap for 2007: Syneron This Israel-based aesthetic laser company has financials that need no cosmetic touch-ups. Investors, take note. |
The Motley Fool
April 10, 2007
Rich Duprey |
The Beauty of Lasers With aesthetic laser treatments booming, which company looks the best? Candela... Cutera... Palomar Medical Technologies... Cynosure... Syneron... |
The Motley Fool
November 11, 2008
Brian Orelli |
Two Years of Red Aesthetic laser makers have been rocked over the last few years. |
The Motley Fool
February 13, 2006
Stephen D. Simpson |
Will Syneron Defy History? Publicly traded laser companies have a legacy of failure; will Syneron manage to turn that tide? |
The Motley Fool
August 15, 2008
Brian Orelli |
Syneron Medical's Bipolar Growth While U.S. sales sink, international sales are keeping the medical laser making company afloat. |
The Motley Fool
February 4, 2008
Kristin Graham |
Best International Stock: Syneron Medical A quick summary of Israeli medical device maker Syneron, a company that could keep you and your portfolio both looking young and healthy. |
The Motley Fool
February 13, 2007
Rich Duprey |
Palomar's Parallax View A plethora of one-time revenues skewed the aesthetic laser maker's results. Investors, take note. |
The Motley Fool
June 14, 2005
Stephen D. Simpson |
Syneron Aims for Cellulite An FDA approval gives Israel's Syneron the lead in non-surgical cellulite treatment. With robust profit margins, that additional revenue could make a big impact on the bottom line. Investors, take note. |
The Motley Fool
February 11, 2005
Stephen D. Simpson |
Laser Beamer Lookin' Good Palomar continues to build a profitable business in the highly competitive cosmetic laser market. |
The Motley Fool
September 22, 2008
Brian Orelli |
Syneron Irons Out Some Wrinkles The aesthetic device maker gets a new product approved in Europe. |
The Motley Fool
May 8, 2007
Rich Duprey |
Cutera's Ugly Quarter The aesthetic laser maker's weak domestic sales dim the outlook for the rest of the year. Investors, take note. |
The Motley Fool
January 10, 2006
Rich Duprey |
Biolase Brightens Outlook The aesthetic laser company expects to be cash flow-neutral on flat revenues. Investors cheer. |
The Motley Fool
April 30, 2007
Rich Duprey |
Foolish Forecast: Cutera Zaps Quarter Investors, don't expect the aesthetic laser maker to burn up the growth charts when it reports first-quarter results. |
The Motley Fool
May 12, 2006
Rich Duprey |
Cutera Continues to Burn The aesthetic laser maker is at risk of losing a patent lawsuit against a competitor. Investors, patents by themselves should not be considered a sufficient competitive moat to induce investment in a company. |
